Risk Factors for Clostridium Difficile Infection in a Tertiary Care Hospital

Muralidhar Varma, Neha Agrawal, Pallavi Uppal, Rahul Singh, Karunya Jayasimha, Shashidhar Vishwanath


Introduction: Clostridium difficile infections have had significant morbidity and mortality in the last decade leading to high healthcare costs. Our prospective case-control study from October 2013 to May 2015 in a tertiary care hospital in rural India aimed to evaluate the risk factors, treatment, outcome, and complications of Clostridium difficile infections in hospitalized patients.

Materials and Methods: The study involved a total of 183 patients, of which 61 were cases, and 122 were controls. Data was analyzed using multivariate logistic regression.

Results: Antibiotic intake in the past four weeks (p=0.003), hypoalbuminemia (p=0.001) and duration of hospital stay before the onset of diarrhea (p<0.001) were proven to have significant risk. We subdivided cases into severe and non-severe cases, and we found that complications were statistically higher in severe cases (OR= 1.685, <0.001).

Conclusion: Identifying severe cases and administering timely and appropriate treatment is prudent.


Clostridium difficile, risk factors, management, severity score

Full Text:



Young VB, Hanna PC. Overlapping roles for toxins in Clostridium difficile infection. J Infect Dis 2014; 209: 9–11.

Bobo LD, Dubberke ER, Kollef M. Clostridium difficile in the ICU: the struggle continues. Chest 2011; 140: 1643-1653.

van der Kooi TI, Koningstein M, Lindemans A, et al. Antibiotic use and other risk factors at hospital level for outbreaks with Clostridium difficile PCR ribotype 027. J Med Microbiol2008; 57: 709-716.

Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-7.

Carignan A, Allard C, Pépin J, Cossette B, Nault V, Valiquette L. Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. Clin Infect Dis 2008; 46:1838-43.

Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infec- tion epidemiology. Clin Infect Dis 2012; 55: Suppl 2: S65-S70.

Yang BK, Do BJ, Kim EJ, et al. The Simple Predictors of Pseudomembranous Colitis in Patients with Hospital-Acquired Diarrhea: A Prospective Observational Study. Gut and Liver. 2014;8(1):41-48.

Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridiumdifficileinfection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.

Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. ClinMicrobiol Infect. 2014;20(suppl 2):1-26.

Khanafer N, Touré A, Chambrier C. Predictors of Clostridium difficile infection severity in patients hospitalised in medical intensive care. World J Gastroenterol 2013; 19:8034–8041.

Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections. ClinMicrobiol Rev 2010; 23: 529–549.

Morrison RH, Hall NS, Said M, et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis 2010;53: 1173–1178.

McCarter MD, Abularrage C, Velasco FT, Davis JM, Daly JM. Diarrhea and Clostridium difficile-associated diarrhea on a surgical service. Arch Surg1996; 131:1333-1337.

Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989-2995.

Henrich TJ, Krakower D, Bitton A, Yokoe DS. Clinical risk factors for severe Clostridium difficile associated disease. Emerg Infect Dis 2009; 15: 415–422.

Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm 2007; 64: 2359-2363.

Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother2007; 51: 2883-2887.

Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170: 784–790.

Kurti Z, Lovasz BD, Mandel MD, et al. Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe. World J Gastroenterol 2015; 21(21): 6728-6735.

Kelly CP, LaMont JT. Clostridium difficile: more difficult than ever. N Engl J Med 2008; 359:1932-1940.

Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: An Underappreciated and Increasing Cause of Death and Complications. Annals of Surgery. 2002;235(3):363-372.

Varkonyi I, Rakoczi E, Misak O, et al. Findings of a hospital surveillance-based outcome evaluation study for Clostridium difficile-associated colitis. ClinMicrobiol Infect. 2014; 20(10):1085-90.


  • There are currently no refbacks.